Atossa Therapeutics Company Description

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.

The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.

Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Atossa Therapeutics, Inc.

Country	United States
Founded	2008
Industry	Biological Products, Except Diagnostic Substances
Employees	15
CEO	Steven Quay

Contact Details

Address: 107 Spring Street Seattle, Delaware 98104 United States
Phone	206-588-0256
Website	atossatherapeutics.com

Stock Details

Ticker Symbol	ATOS
Exchange	Mexican Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Steven Quay	Chief Executive Officer
Heather Rees	Chief Financial Officer
Michael Parks	Head of Investor Relations